Biodiversity Treaty: A 'Lose-Lose' Proposition For U.S. Consumers, Scientists, And Industry

Consumers, Scientists, And Industry Author: Henry I. Miller. The 1992 "Biodiversity Treaty," rejected by the Bush administration but signed by President Clinton, faces opposition to ratification in the Republican-controlled Senate. But the treaty, a lose-lose proposition for United States consumers, scientists, and industry alike, is a bad idea that won't die. It remains high on the administration's agenda. Speaking at Stanford University on April 26, Tim Wirth, undersecretary of state for glo

Written byHenry Miller
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Consumers, Scientists, And Industry Author: Henry I. Miller.


The 1992 "Biodiversity Treaty," rejected by the Bush administration but signed by President Clinton, faces opposition to ratification in the Republican-controlled Senate. But the treaty, a lose-lose proposition for United States consumers, scientists, and industry alike, is a bad idea that won't die. It remains high on the administration's agenda. Speaking at Stanford University on April 26, Tim Wirth, undersecretary of state for global affairs, said it has the "top priority among all treaties" and agreements awaiting confirmation. Moreover, Vice President Al Gore is known to be willing to make almost any political deal for its approval.

The treaty (more formally, the Convention on Biological Diversity) addresses a broad spectrum of issues related to the protection of biological diversity. These include the conservation of habitats in developing nations and the availability of resources to make this possible. The treaty was conceived as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies